keyword
MENU ▼
Read by QxMD icon Read
search

Adjuvant sunitinib

keyword
https://www.readbyqxmd.com/read/27930642/adjuvant-treatment-for-renal-cell-carcinoma-do-we-finally-have-a-major-breakthrough
#1
Devin N Patel, Robert A Figlin, Hyung L Kim
Clinical parameters can be used to identify patients at greatest risk for recurrence following nephrectomy for clinically localized renal cell carcinoma (RCC). Molecular tools are being developed to improve risk stratification. An increasing list of available treatments for metastatic RCC continues to provide hope that an effective adjuvant therapy will be identified for patients with high-risk, clinically localized disease. In a phase 3 adjuvant therapy trial (S-TRAC), sunitinib increased median disease-free survival in patients with clear cell RCC who were at very high risk...
November 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27928797/-changes-of-diagnosis-and-treatment-for-gastrointestinal-stromal-tumors-during-a-18-year-period-in-four-medical-centers-of-china
#2
Haibo Qiu, Peng Zhang, Xingyu Feng, Tao Chen, Xiaowei Sun, Jiang Yu, Zhijing Chen, Yong Li, Kaixiong Tao, Guoxin Li, Zhiwei Zhou
OBJECTIVE: To elucidate the historic and current diagnosis and treatment status of gastrointestinal stromal tumor (GIST) in the Chinese population based on four high volume databases. METHODS: Clinicopathological data of GIST patients with follow-up information between January 1998 and December 2015 from Sun Yat-sen University Cancer Center, Union Hospital of Huazhong University of Science and Technology, Southern Medical University Nanfang Hospital and Guangdong General Hospital were retrospectively analyzed...
November 25, 2016: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/27900022/conversion-of-aspergilloma-to-chronic-necrotizing-pulmonary-aspergillosis-following-treatment-with-sunitinib-a-case-report
#3
Yeon Wook Kim, Hyun Woo Lee, Jaeyoung Cho, Han-Sol Choi, Jungsil Lee, Sung Soo Park, Eun Young Heo, Kwang Nam Jin, Deog Kyeom Kim
Semi-invasive or invasive aspergillosis occurring following chemotherapy with sunitinib is a rare condition with unknown incidence and prognosis. Here, we report a case involving a 59-year-old male who had a history of underlying stable aspergilloma and was newly diagnosed with metastatic renal cell carcinoma. Following surgical resection for renal cell carcinoma and adjuvant chemotherapy with sunitinib for 8 months, the patient presented with hemoptysis. Chest computed tomography revealed an increased soft tissue mass and air crescent sign of the underlying aspergilloma, combined with consolidation and bronchial artery hypertrophy around the lesion...
November 2016: Oncology Letters
https://www.readbyqxmd.com/read/27773485/sunitinib-as-adjuvant-therapy-for-renal-cell-carcinoma
#4
Holly Baker
No abstract text is available yet for this article.
October 20, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27718781/adjuvant-sunitinib-in-high-risk-renal-cell-carcinoma-after-nephrectomy
#5
Alain Ravaud, Robert J Motzer, Hardev S Pandha, Daniel J George, Allan J Pantuck, Anup Patel, Yen-Hwa Chang, Bernard Escudier, Frede Donskov, Ahmed Magheli, Giacomo Carteni, Brigitte Laguerre, Piotr Tomczak, Jan Breza, Paola Gerletti, Mariajose Lechuga, Xun Lin, Jean-Francois Martini, Krishnan Ramaswamy, Michelle Casey, Michael Staehler, Jean-Jacques Patard
Background Sunitinib, a vascular endothelial growth factor pathway inhibitor, is an effective treatment for metastatic renal-cell carcinoma. We sought to determine the efficacy and safety of sunitinib in patients with locoregional renal-cell carcinoma at high risk for tumor recurrence after nephrectomy. Methods In this randomized, double-blind, phase 3 trial, we assigned 615 patients with locoregional, high-risk clear-cell renal-cell carcinoma to receive either sunitinib (50 mg per day) or placebo on a 4-weeks-on, 2-weeks-off schedule for 1 year or until disease recurrence, unacceptable toxicity, or consent withdrawal...
October 9, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27651308/efficacy-of-cotargeting-angiopoietin-2-and-the-vegf-pathway-in-the-adjuvant-postsurgical-setting-for-early-breast-colorectal-and-renal-cancers
#6
Florence T H Wu, Shan Man, Ping Xu, Annabelle Chow, Marta Paez-Ribes, Christina R Lee, Steven R Pirie-Shepherd, Urban Emmenegger, Robert S Kerbel
Antiangiogenic tyrosine kinase inhibitors (TKI) that target VEGF receptor-2 (VEGFR2) have not been effective as adjuvant treatments for micrometastatic disease in phase III clinical trials. Angiopoietin-2 (Ang2) is a proangiogenic and proinflammatory vascular destabilizer that cooperates with VEGF. The purpose of this study was to test whether CVX-060 (an Ang2-specific CovX-body) can be combined with VEGFR2-targeting TKIs (sunitinib or regorafenib) to successfully treat postsurgical metastatic disease in multiple orthotopically implanted human tumor xenograft and syngeneic murine tumor models...
December 1, 2016: Cancer Research
https://www.readbyqxmd.com/read/27546844/knowns-and-known-unknowns-of-gastrointestinal-stromal-tumor-adjuvant-therapy
#7
REVIEW
Virginia Martínez-Marín, Robert G Maki
The first 15 years of management of gastrointestinal stromal tumor (GIST) have led to 3 lines of therapy for metastatic disease: imatinib, sunitinib, and regorafenib. In the adjuvant setting, imatinib is usually given for 3 years postoperatively to patients with higher-risk primary tumors that are completely resected. In this review, issues regarding GIST adjuvant therapy are discussed. It is hoped this review will help the reader understand the present standard of care to improve upon it in years to come...
September 2016: Gastroenterology Clinics of North America
https://www.readbyqxmd.com/read/27146754/current-evidence-and-the-evolving-role-of-sunitinib-in-the-management-of-renal-cell-carcinoma
#8
V Noronha, A Joshi, G Bakshi, H Tongaonkar, K Prabhash
The development of targeted agents has expanded the anticancer arsenal available to oncologists and revolutionized the field of cancer treatment. In patients with advanced renal cell carcinoma (RCC), small molecule targeted therapies have improved clinical outcomes compared with cytokine-based treatments. Sunitinib malate is one such drug that has demonstrated clinical efficacy in patients with metastatic renal cell carcinoma (mRCC). This oral, multi-targeted tyrosine kinase inhibitor is approved for use in multiple countries for the treatment of advanced RCC and gastrointestinal stromal tumor patients who have progressed on imatinib therapy...
January 2016: Indian Journal of Cancer
https://www.readbyqxmd.com/read/27085828/does-timing-of-targeted-therapy-for-metastatic-renal-cell-carcinoma-impact-treatment-toxicity-and-surgical-complications-a-comparison-of-primary-and-adjuvant-approaches
#9
Nishant Patel, Jason Woo, Michael A Liss, Kerrin L Palazzi, J Michael Randall, Reza Mehrazin, Ramzi Jabaj, Hossein S Mirheydar, Kyle Gillis, Hak J Lee, Anthony L Patterson, Christopher J Kane, Frederick Millard, Ithaar H Derweesh
INTRODUCTION: To compare surgical complications and tyrosine kinase inhibitor (TKI)-toxicities in patients who underwent primary cytoreductive nephrectomy (CN) followed by adjuvant TKI therapy versus those who underwent neoadjuvant TKI therapy prior to planned CN for metastatic renal cell carcinoma (mRCC). MATERIALS AND METHODS: Two-center retrospective analysis. Sixty-one mRCC patients underwent TKI therapy with sunitinib between July 2007 to January 2014. Patients were divided into three groups: primary CN followed by adjuvant TKI (n = 27, Group 1), neoadjuvant TKI prior to CN (n = 21, Group 2), and primary TKI alone (no surgery, n = 13, Group 3)...
April 2016: Canadian Journal of Urology
https://www.readbyqxmd.com/read/27065683/gastrointestinal-stromal-tumor-mimicking-as-ovarian-tumor-in-gynaecologic-oncology
#10
Santosh K Ijeri, Praveen S Rathod, Rajshekar Kundargi, V R Pallavi, K Shobha, Shankaranand, C R Vijay, K Uma Devi, Uttam D Bafna
To report the clinical presentation and outcomes of a series of patients who presented with abdominal/pelvic mass or pelvic pain and were diagnosed with a gastrointestinal stromal tumor (GIST). Retrospective data were collected of all patients who presented with an abdominal/pelvic mass or pelvic pain between January 2010 and July 2015 and who were ultimately diagnosed with a GIST. The patients' medical records were reviewed. A literature review was also conducted. The event free survival and overall survival was calculated for all patients using Kaplan Meier curve (SPSS19-SPSS Inc...
March 2016: Indian Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27030525/kidney-cancer-no-advantage-of-adjuvant-sunitinib-or-sorafenib
#11
Louise Stone
No abstract text is available yet for this article.
May 2016: Nature Reviews. Urology
https://www.readbyqxmd.com/read/26994026/targeted-therapy-for-renal-cell-carcinoma
#12
R Joshi, S Rawal
INTRODUCTION: Our study aims to evaluate the use of targeted therapy in metastatic renal cell carcinoma Methods: This is a prospective study done over three years from December 2010 to December, 2013.Out of Forty seven patients of metastatic renal cell carcinoma 8(neo-adjuvant cases) were excluded and 39 were included in this study. All patients received Tyrosine kinase inhibitor, sunitinib therapy (50 mg OD, 4/2 scheme). All 39 patients underwent radical nephrectomy prior to sunitinib therapy...
April 2015: JNMA; Journal of the Nepal Medical Association
https://www.readbyqxmd.com/read/26969090/adjuvant-sunitinib-or-sorafenib-for-high-risk-non-metastatic-renal-cell-carcinoma-ecog-acrin-e2805-a-double-blind-placebo-controlled-randomised-phase-3-trial
#13
RANDOMIZED CONTROLLED TRIAL
Naomi B Haas, Judith Manola, Robert G Uzzo, Keith T Flaherty, Christopher G Wood, Christopher Kane, Michael Jewett, Janice P Dutcher, Michael B Atkins, Michael Pins, George Wilding, David Cella, Lynne Wagner, Surena Matin, Timothy M Kuzel, Wade J Sexton, Yu-Ning Wong, Toni K Choueiri, Roberto Pili, Igor Puzanov, Manish Kohli, Walter Stadler, Michael Carducci, Robert Coomes, Robert S DiPaola
BACKGROUND: Renal-cell carcinoma is highly vascular, and proliferates primarily through dysregulation of the vascular endothelial growth factor (VEGF) pathway. We tested sunitinib and sorafenib, two oral anti-angiogenic agents that are effective in advanced renal-cell carcinoma, in patients with resected local disease at high risk for recurrence. METHODS: In this double-blind, placebo-controlled, randomised, phase 3 trial, we enrolled patients at 226 study centres in the USA and Canada...
May 14, 2016: Lancet
https://www.readbyqxmd.com/read/26905101/regorafenib-a-novel-tyrosine-kinase-inhibitor-a-brief-review-of-its-therapeutic-potential-in-the-treatment-of-metastatic-colorectal-carcinoma-and-advanced-gastrointestinal-stromal-tumors
#14
REVIEW
P Thangaraju, H Singh, A Chakrabarti
Regorafenib is a novel oral multitargeted tyrosine kinase inhibitor having both antitumor and anti-angiogenic activities. Regorafenib was recently approved by US Food and Drug Administration in February 25, 2013 in the treatment for patients with advanced gastrointestinal stromal tumor and for the treatment of patients with metastatic colorectal carcinoma after disease progression or intolerance to imatinib mesylate and sunitinib therapy. Oral regorafenib demonstrates a high level of efficacy with acceptable tolerability with the 160 mg daily for 3 weeks followed by 1 week off schedule; a continuous schedule could be of interest...
July 2015: Indian Journal of Cancer
https://www.readbyqxmd.com/read/26870842/thyroid-nodule-not-as-clear-cut-as-it-seems
#15
Gilbert Bader, Igor Puzanov, Kanishka Chakraborty
Benign etiologies and primary thyroid cancers are the most common causes of incidental thyroid nodules. Clinically evident metastases to the thyroid gland are not common and account for 2%-3% of thyroid cancers, though the incidence of thyroid metastases reaches 24% in autopsy studies.1 The most common clinically detected thyroid metastases originate from renal cell carcinoma (RCC; 48.1%).2 We report here a rare case of a man with clear-cell RCC with late recurrence in the thyroid gland as a solitary metastasis, 13 years after the primary diagnosis...
January 2016: Journal of Community and Supportive Oncology
https://www.readbyqxmd.com/read/26870284/evolution-and-prognosis-of-breast-osteosarcoma-a-case-report
#16
Wanfeng Guo, Yang Cao, Guangju Teng, Jin Liu, Jianbin Su
Breast osteosarcoma is a rare malignancy of unknown etiology, with no standard adjuvant treatment at present. The prognosis of the disease is poor, and it has a high propensity for recurrence and metastasis. The current report presents the case of a 52-year-old woman, in whom adenomyoepithelioma gradually developed into breast osteosarcoma following three separate surgeries. The patient survived for 41 months from the initial lesion occurrence and resection in the left breast; during this time, she underwent surgery and chemotherapy (liposomal doxorubicin and cisplatin) for the treatment of disease recurrence and lung metastasis, along with molecular-targeted therapy (sunitinib)...
January 2016: Oncology Letters
https://www.readbyqxmd.com/read/26820287/the-role-of-surgery-in-metastatic-gastrointestinal-stromal-tumors
#17
Emily Z Keung, Mark Fairweather, Chandrajit P Raut
Gastrointestinal stromal tumors (GISTs) are the most common sarcomas and mesenchymal neoplasms of the gastrointestinal tract. Macroscopically complete (R0/R1) resection is the standard treatment for localized resectable GIST with adjuvant imatinib therapy recommended for patients with intermediate or high-risk disease. In patients with advanced unresectable or metastatic GIST, imatinib has significantly improved outcomes. However, while most patients achieve partial response (PR) or stable disease (SD) on imatinib (with maximal response typically seen by 6 months on treatment), approximately half will develop secondary resistance by 2 years...
February 2016: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/26770446/consumptive-hypothyroidism-due-to-a-gastrointestinal-stromal-tumor-expressing-type-3-iodothyronine-deiodinase
#18
Lin-Hai Yan, Xian-Wei Mo, Yu-Zhou Qin, Cheng Wang, Zhi-Ning Chen, Yuan Lin, Jian-Si Chen
CONTEXT: Gastrointestinal stromal tumors (GISTs) are responsive to sunitinib (the tyrosine kinase inhibitor), this agent is widely used in prevention relapse of GISTs and neo-adjuvant chemotherapy in GIST patients without operation opportunity. The use of these agents has both advantages and disadvantages. On the one hand, it can improve the outcome for patient. On the other hand, it may lead to consumptive hypothyroidism, a rare syndrome caused by increased catabolism of T4 and T3 by increased type 3 iodothyronine deiodinase (D3) activity...
2015: International Journal of Clinical and Experimental Medicine
https://www.readbyqxmd.com/read/26672673/state-of-the-art-in-the-treatment-of-gastrointestinal-stromal-tumors
#19
REVIEW
Benjami Garlipp, Christiane J Bruns
BACKGROUND: Gastrointestinal stromal tumors (GISTs) are the most frequently diagnosed mesenchymal neoplasms of the gastrointestinal tract. Despite their biological and clinical heterogeneity, the majority of these tumors are positive for the receptor tyrosine kinase KIT and are driven by KIT- or platelet-derived growth factor receptor alpha (PDGFRA)-activating mutations. There are still uncertainties regarding their clinical and molecular characterization and the optimal treatment regimens, making it difficult to establish a universal treatment algorithm for these tumors...
May 2014: Gastrointestinal Tumors
https://www.readbyqxmd.com/read/26671977/phase-2-clinical-trial-of-sunitinib-as-adjunctive-treatment-in-patients-with-advanced-differentiated-thyroid-cancer
#20
Athanasios Bikas, Priya Kundra, Sameer Desale, Mihriye Mete, Kaitlyn O'Keefe, Brandon G Clark, Lynette Wray, Rahul Gandhi, Christina Barett, James S Jelinek, Jason A Wexler, Leonard Wartofsky, Kenneth D Burman
OBJECTIVE: Our objective was to evaluate the efficacy and safety of sunitinib following at least one course of radioactive iodine treatment in patients with advanced differentiated thyroid cancer (DTC). The study endpoints included best response rate (including best objective response rate) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, measurement of serum thyroglobulin (Tg), and toxicity evaluation. DESIGN AND METHODS: This was a single center, nonrandomized, open-label, phase 2 clinical trial...
March 2016: European Journal of Endocrinology
keyword
keyword
110017
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"